Mario Matthaei

Mario Matthaei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mario Matthaei has a total of 134 co-authors. Here are the top co-authors by number of shared publications:

  • Claus Cursiefen

    Department of Ophthalmology (C.C., M.M.), University of Cologne, Cologne, Germany

    13 shared publications
  • Björn Bachmann

    Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany

    9 shared publications
  • Claus Cursiefen

    Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany

    8 shared publications
  • Sebastian Siebelmann

    From the Department of Ophthalmology (A.H., M.M., T.C., N.R., F.F., A.H., S.S., B.O.B., C.C., M.M), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany

    6 shared publications
  • Sebastian Siebelmann

    Department of Ophthalmology, University of Cologne, Cologne, Germany

    6 shared publications
  • Björn O. Bachmann

    From the Department of Ophthalmology (A.H., M.M., T.C., N.R., F.F., A.H., S.S., B.O.B., C.C., M.M), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany

    5 shared publications

Latest Publications

  • Delphi-Based Global Consensus on Fuchs Endothelial Corneal Dystrophy. An Endothelial Keratoplasty Learners Group Initiative

    by Sanjay V. Patel, Nidhi Gupta, Maninder Bhogal, Ula V. Jurkunas, Naoki Okumura, Vito Romano, Bruce D. Allan, Keith H. Baratz, Samar K. Basak, Lamis Baydoun, et al.


  • Fuchs-Endotheldystrophie: Diagnose und Therapie

    by Mario Matthaei, Mert Mestanoglu, Björn Bachmann, Claus Cursiefen

  • Fuchs-Endotheldystrophie: Diagnose und Therapie

    by Mario Matthaei, Mert Mestanoglu, Björn Bachmann, Claus Cursiefen

  • Artificial Intelligence for Lamellar Keratoplasty

    by Sebastian Siebelmann, Takahiko Hayashi, Mario Matthaei, Björn O. Bachmann, Johannes Stammen, Claus Cursiefen

    The training of artificial intelligence (AI) is becoming increasingly popular. More and more studies on lamellar keratoplasty are also being published. In particular, the possibility of non-invasive and high-resolution imaging technology of optical coherence tomography predestines lamellar keratoplasty for the application of AI. Although it is technically easy to perform, there are only a few studies on the use of AI to optimise lamellar keratoplasty. The existing studies focus primarily on the prediction probability of rebubbling in DMEK and DSAEK and on their graft adherence, as well as on the formation of a big bubble in DALK. In addition, the automated recording of routine parameters such as corneal oedema, endothelial cell density or the size of the graft detachment is now possible using AI. The optimisation of lamellar keratoplasty using AI holds great potential. Nevertheless, there are limitations to the published algorithms, in that they can only be transferred between centres, surgeons and different device manufacturers to a limited extent.


  • Implementation and Execution of Big Data-based Studies in Ophthalmology within the Framework of the GDPR

    by Benedikt Siebelmann, Guido Grass, Mario Matthaei, Claus Cursiefen, Till Gerhardt, Juliane Koeberlein-Neu, Sebastian Siebelmann

    The processing of the retrospective data pool for ophthalmology holds huge potential, especially for the research sector. “Big Data” enables medical science to draw conclusions for the future from historical data. Based on the evaluation of such data, algorithms could be trained, for instance, that are capable of making decisions with the help of artificial intelligence. As a result, the medical decision-making process on certain issues could be accelerated, enriched in qualitative and quantitative terms, or even completely be taken over. Ophthalmology is a rapidly evolving field. Due to the multitude of partly automated medical imaging technologies and the predestined accessibility of the eye for such technologies, ophthalmology, similarly to radiology or dermatology, is well suited for artificial intelligence-assisted image data analysis and the frequently associated initiation of diagnosis and therapy. Meanwhile, numerous studies exist based on AI-assisted image data analysis of ophthalmological image data. To the extent that the algorithms filter out results from the data pools by means of calculation rules and are even capable of making independent decisions on the basis of decision trees, the enormous benefit and, simultaneously, the profit for scientific research is quite obvious. Accordingly, it would be desirable to have unrestricted and comprehensive possibility of corresponding data processing of these health data for ophthalmological research. In spite of the potential for ophthalmology, for which there is only fragmentary evidence, the question of practical feasibility arises. In particular, the legal requirements and limits of European and national data protection law must be taken into account, prior to any unreflected processing of personal (health) data. Only by doing so can we circumvent existing obstacles and pitfalls, which can lead to severe fines. Most important are to date the requirements of two legal texts: The General Data Protection Regulation (GDPR) and the Federal Data Protection Act (BDSG). This article provides an overview of the relevant legal requirements applicable in the field of ophthalmology and highlights the major pitfalls and implementation requirements.


  • Blut-Kammerwasser-Schranken-Störungen bei perforierender und posteriorer lamellärer Keratoplastik: Implikationen für das klinische Ergebnis

    by Mario Matthaei, Anne Fassin, Mert Mestanoglu, Antonia Howaldt, Silvia Andreea Schrittenlocher, Simona Schlereth, Sigrid Roters, Rafael S. Grajewski, Björn O. Bachmann, Claus Cursiefen

    Zusammenfassung: Hintergrund Die Blut-Kammerwasser-Schranke (BKS) grenzt immunprivilegiertes Gewebe des Auges von der Blutzirkulation ab. Die Störung der BKS stellt somit einen Risikofaktor für Abstoßungsreaktionen nach Keratoplastik dar. Ziel der Arbeit Die vorliegende Arbeit bietet eine Übersicht der Arbeiten unserer und anderer Arbeitsgruppen zu BKS-Störungen bei perforierender (PKPL) und posteriorer lamellärer Keratoplastik sowie deren Implikationen für das klinische Ergebnis. Methoden Es erfolgte eine PubMed-Literaturrecherche zur Erstellung einer Übersichtsarbeit. Ergebnis Die Laser-Flare-Photometrie bietet ein objektives und reproduzierbares Verfahren zur Beurteilung der Integrität der BKS. Untersuchungen des Flares nach perforierender und posteriorer lamellärer Keratoplastik belegen eine im postoperativen Verlauf meist rückläufige Störung der BKS, die in Ausmaß und Dauer durch multiple Faktoren beeinflusst wird. Persistierend erhöhte Flare-Werte oder ein Anstieg des Flares nach zunächst postoperativer Regeneration können dabei auf ein erhöhtes Abstoßungsrisiko hinweisen. Diskussion Bei persistierend oder im postoperativen Verlauf rezidivierend erhöhten Flare-Werten nach Keratoplastik ist eine intensivierte (lokale) Immunsuppression möglicherweise sinnvoll. Dies könnte zukünftig, insbesondere beim Monitoring von Patienten nach Hochrisiko-Keratoplastik, Bedeutung erlangen. Ob ein Anstieg des Laser-Flares ein reliabler Frühindikator einer drohenden Immunreaktion nach PKPL oder posteriorer lamellärer Keratoplastik ist, müssen jedoch prospektive Studien zeigen.


  • Corneal Hydrops – Aetiology and Advanced Therapeutic Strategies

    by Björn O. Bachmann, Mario Matthaei, Simona Schlereth, Claus Cursiefen

    Acute hydrops refers to sudden corneal edema caused by rupture of Descemetʼs membrane (DM) – often in progressive keratectasia. It leads to a sudden decrease in visual acuity, pain, and foreign body sensation as well as an increased glare sensation. Acute hydrops usually heals with scarring within months, but complications such as corneal perforation, infectious keratitis, and corneal vascularization may occur. The prevalence in keratoconus patients is 2.6 to 2.8%. Risk factors include keratoconjunctivitis vernalis, atopic dermatitis, high keratometry, male gender, and eye rubbing. Keratoplasty should be avoided in the acute phase. The prognosis of the graft is reduced, and after scar healing of the hydrops, wearing contact lenses or glasses may be possible again. Conservative therapy alone with lubricants and hyperosmolar eye drops, prophylactic antibiotic eye drops to prevent superinfection, and topical steroids was long considered the only possible form of treatment. However, healing under conservative therapy takes an average of over 100 days. In the meantime, there are different surgical strategies that rapidly shorten the healing and thus the recovery phase of the patients to a few days. If the DM is detached without tension, a simple injection of gas into the anterior chamber can already lead to reattachment and thus to almost immediate deswelling of the cornea. If the DM is under tension, predescemetal sutures combined with a gas injection into the anterior chamber can flatten the cornea and reattach the DM. Mini-Descemet membrane endothelial keratoplasty (mini-DMEK) allows for sutureless closure of the DM defect by transplantation of a small (< 5 mm) graft. In cases of particularly large DM tears and very pronounced hydrops, suture loosening and relapse may occur after the placement of predescemetal sutures. Mini-DMEK can then lead to permanent healing, but in contrast to simple corneal sutures, it is usually performed under general anesthesia and by aid of intraoperative optical coherence tomography. The very good results with regard to the rapid healing prove that surgical therapy makes sense in the vast majority of patients with acute hydrops and should be initiated quickly.


  • Open Access

    Correlation of Clinical Fibrillar Layer Detection and Corneal Thickness in Advanced Fuchs Endothelial Corneal Dystrophy

    by Orlando Özer, Mert Mestanoglu, Antonia Howaldt, Thomas Clahsen, Petra Schiller, Sebastian Siebelmann, Niklas Reinking, Claus Cursiefen, Björn Bachmann, Mario Matthaei

    Central subendothelial geographic deposits are formed as a fibrillar layer (FL) in advanced Fuchs endothelial corneal dystrophy (FECD). Previous studies demonstrated a significant decrease in corneal endothelial cell (CEC) density and an increase in focal corneal backscatter in the FL area. The present study investigated the association of the FL with edema formation and its localization. Patients (n = 96) presenting for Descemet membrane endothelial keratoplasty (DMEK) for advanced FECD were included. Slit-lamp biomicroscopy with FECD grading was followed by Scheimpflug imaging with en face backscatter analysis and pachymetric analysis. FL dimensions were measured, and correlation with pachymetric values was performed. An FL was detected in 74% of all eyes (n = 71). Pachymetric values in FL-positive versus FL-negative eyes were for corneal thickness at the apex (ACT) 614 ± 52 µm and 575 ± 46 µm (p = 0.001), for peripheral corneal thickness at 1 mm (PCT1mm) 616 ± 50 µm and 580 ± 44 µm (p = 0.002), for PCT2mm 625 ± 48 µm and 599 ± 41 µm (p = 0.017), for PCT3mm 651 ± 46 µm and 635 ± 40 µm (p = 0.128) and for PCT4mm 695 ± 52 µm and 686 ± 43 µm (p = 0.435), respectively. Correlation analysis indicated a weak correlation for the FL maximum vertical caliper diameter with ACT and PCT1mm values but no further relevant correlations. In FL-positive eyes, increased focal corneal backscatter and increased corneal thickness showed primarily central and inferotemporal localization. In conclusion, Scheimpflug imaging shows an association of the FL with increased corneal thickness in advanced FECD and shows localization of the FL and increased corneal thickness in the central and inferotemporal region. This may provide important information for progression assessment and therapeutic decision making in FECD patients in the future.